Walleye Capital LLC Sells 494,706 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)

Walleye Capital LLC cut its holdings in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 96.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 18,117 shares of the company's stock after selling 494,706 shares during the quarter. Walleye Capital LLC's holdings in Perspective Therapeutics were worth $242,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of CATX. WealthPlan Investment Management LLC acquired a new stake in shares of Perspective Therapeutics in the 3rd quarter valued at about $4,530,000. Hills Bank & Trust Co bought a new position in shares of Perspective Therapeutics during the third quarter worth about $13,722,000. Nicholson Wealth Management Group LLC acquired a new stake in Perspective Therapeutics in the 3rd quarter valued at approximately $21,390,000. FMR LLC lifted its stake in Perspective Therapeutics by 3,994.9% in the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company's stock valued at $73,489,000 after acquiring an additional 5,370,392 shares in the last quarter. Finally, WealthPLAN Partners LLC acquired a new position in Perspective Therapeutics during the 2nd quarter worth approximately $1,695,000. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Stock Down 5.5 %

Shares of CATX stock traded down $0.20 on Wednesday, reaching $3.45. The stock had a trading volume of 1,544,443 shares, compared to its average volume of 860,918. Perspective Therapeutics, Inc. has a 12 month low of $2.28 and a 12 month high of $19.05. The firm's 50-day moving average is $9.19 and its two-hundred day moving average is $11.65.

Perspective Therapeutics (NYSE:CATX - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.21). Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. The firm had revenue of $0.37 million for the quarter. Sell-side analysts predict that Perspective Therapeutics, Inc. will post -0.88 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Cantor Fitzgerald reiterated an "overweight" rating on shares of Perspective Therapeutics in a report on Monday, September 9th. Oppenheimer decreased their target price on shares of Perspective Therapeutics from $22.00 to $16.00 and set an "outperform" rating for the company in a research report on Friday, November 22nd. Bank of America cut shares of Perspective Therapeutics from a "buy" rating to a "neutral" rating and cut their price target for the stock from $24.00 to $5.00 in a research report on Monday, November 25th. Royal Bank of Canada reduced their price objective on shares of Perspective Therapeutics from $25.00 to $16.00 and set an "outperform" rating for the company in a research note on Monday, November 25th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $11.00 target price (down previously from $20.00) on shares of Perspective Therapeutics in a research report on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $15.14.

Insider Buying and Selling at Perspective Therapeutics

In related news, Director Heidi Henson acquired 25,975 shares of the business's stock in a transaction on Wednesday, December 4th. The stock was purchased at an average cost of $3.85 per share, for a total transaction of $100,003.75. Following the completion of the transaction, the director now directly owns 25,975 shares of the company's stock, valued at approximately $100,003.75. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Jonathan Robert Hunt bought 12,829 shares of the firm's stock in a transaction dated Monday, November 25th. The stock was purchased at an average cost of $3.82 per share, for a total transaction of $49,006.78. Following the transaction, the chief financial officer now directly owns 48,800 shares of the company's stock, valued at $186,416. The trade was a 35.66 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired 67,570 shares of company stock valued at $256,789 in the last quarter. 3.52% of the stock is currently owned by insiders.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.